Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CYAB vs SNYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNYR Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

SNYR Overall Winner 6-Pillar Tally: CYAB 0 – 5 SNYR (1 Tie) Matrix Metrics: CYAB 1 – 9 SNYR

As of Nov 20, 2026, Synergy CHC Corp. (SNYR) is the stronger overall head-to-head candidate over CYAB (CYAB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CYAB carries a Unified Composite Score of 48.4/100 (HOLD) at $0.06 (N/M Forward P/E, N/A operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin).

  • Technical & Structure Timing Caution: CYAB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile SNYR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CYAB vs SNYR
CYAB US Equity
CYAB
Institutional Equity
$0.06
-3.39% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.45β · 246% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 43.0 Fund 52.0 Flow 50.0 Mom 88.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -37.4%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $0.10 · SMA50: $0.17
SNYR NASDAQ Head-to-Head Winner
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14

6-Pillar Scorecard Institutional Category Breakdown (CYAB 0 – 5 SNYR)

Columns: Metric · CYAB · SNYR
1. Valuation Multiples SNYR
Forward P/E N/M 0.6x
Trailing P/E N/M 0.6x
PEG Ratio N/M N/M
EV / Revenue N/M 0.1x
2. Growth & Scale SNYR
Revenue Growth (YoY) N/A -32.8%
Earnings Growth (YoY) N/A -90.6%
TTM Revenue (USD) N/A $28M
Market Cap N/A $4.1M
3. Profitability & Quality SNYR
Gross Margin N/A 65.4%
Operating Margin N/A -10.3%
Net Profit Margin N/A -57.0%
Return on Equity (ROE) N/A -361.1%
4. Balance Sheet & Cash Flow SNYR
Cash Generation (TTM) N/A -$3.8M
Cash Flow Margin N/A -13.7%
Net Cash / Leverage N/A ROE -361.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity N/A 75.7% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CYAB (1) vs SNYR (9)
Institutional Metric CYAB SNYR Criterion Row Edge
Market Capitalization
Scale
N/A $4.1M Larger Scale SNYR
Trailing P/E Ratio
Valuation
N/M 0.6x Lower Multiple SNYR
Forward P/E Ratio
Valuation
N/M 0.6x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
N/A -32.8% Higher Growth SNYR
Operating Margin (TTM)
Profitability
N/A -10.3% Higher Margin SNYR
Net Profit Margin
Profitability
N/A -57.0% Higher Margin SNYR
Return on Equity (ROE)
Capital Efficiency
N/A -361.1% Higher ROE SNYR
52-Week Range Position
Momentum
0% ($0–$6) 1% ($0–$3) Stronger Trend SNYR
Beta / 30D Volatility
Risk Regime
0.45β · 246% Vol -0.86β · 868% Vol Lower Realized Risk CYAB
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite SNYR
Trailing 12M Revenue (USD)
Operating Scale
N/A $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 65.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$3.8M (-361.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CYAB +16.95 pp
CYAB: +0.67% · SNYR: -16.28%
3M Horizon CYAB +12.44 pp
CYAB: -44.2% · SNYR: -56.64%
6M Horizon CYAB +0.65 pp
CYAB: -91.87% · SNYR: -92.52%
1Y Horizon CYAB +0.65 pp
CYAB: -91.87% · SNYR: -92.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CYAB vs SNYR. Trailing 12-month operating profitability (CYAB N/A vs SNYR -10.3%) and valuation multiples (CYAB N/M vs SNYR 0.6x Forward P/E) are benchmarked directly in Pillar 4 below.

CYAB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SNYR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin65.4%
Op. Margin-10.3%
ROE / Fwd P/E-361.1% · 0.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CYAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CYAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CYAB Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ CYAB vs SNYR Key Questions & Quantitative Answers

As of Nov 20, 2026, Synergy CHC Corp. (SNYR) is the stronger overall head-to-head candidate over CYAB (CYAB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CYAB carries a Unified Composite Score of 48.4/100 (HOLD) at $0.06 (N/M Forward P/E, N/A operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin). Technical & Structure Timing Caution: CYAB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile SNYR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SNYR leads the Growth & Scale pillar: CYAB posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SNYR at -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin). On trailing 12-month operating scale, CYAB generates N/A in USD-normalized revenue versus $28M for SNYR. In operating R&D and SG&A reinvestment, CYAB deploys N/A (0 90-day corporate R&D disclosures) versus 75.7% of Rev ($21M) (0 disclosures) for SNYR.

SNYR screens cheaper on headline valuation multiples. CYAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CYAB (N/A ROE) versus SNYR (-361.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CYAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 246% Vol realized risk). By comparison, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.